$RSII WILL B THE NEXT OWCP AND MORE! PLEASE DD IT
Post# of 103014
(Total Views: 455)
Posted On: 02/25/2017 8:03:08 PM
$RSII WILL B THE NEXT OWCP AND MORE! PLEASE DD IT NOW, AND HELP LOCK THE FLOAT BY SLAPPING THE ASK! MM'S ARXS AND ASCM ARE SHORT, HIDING BEHIND NITE AND JUMPING MM'S FOR SHARES! CRAZY! REMEMBER, THESE ARE THE TOP TWO MM'S THAT GOT CAUGHT SHORT OWCP, C HOW THAT WORKED OUT FOR THEM.
$OWCP VS. $RSII Med cannabis sector producst but different biz models>>>
Med Cannabis is very safe and not under the same regs as rec cannabis.
RSII REVIEW OF CONF. CALL on 2/24/17 & DD:
If you missed the Conf. Call yesterday ...here is a good summary and some DD:
RSII business model confirmed today on CC... There model is sort of like OWCP's but without all the FDA guidelines, indications, submission, trials, and all the COSTS that going into getting a product ready to submit to the FDA...That is very risky, costly and may never earn a dime in profit or revenue.....NOW RSII will have A team of pharmacists, chemists, physicians, etc..will be creating pharm grade medicinal cannabis product with the highest quality of ingredients and calibrated with precise accuracy. All forms of cannabis, but mainly topicals, creams, and orals. ..No one in the industry is doing this with precise accuracy...they will be the first... They come short of announcing they will supply to NWAV clinics (Alternative Medicine Centers of America) but if you read between the lines, its pretty much a done deal....Robert Weber is the CEO of both and he basicly said they had to separate the disposing/compounding side from the patient/clinic side as per their lawyers due to regulations. Medicinal Cannabis will be branded and marketed under their name Rising Biosciences. Mail order, clinics, prescribing md's, etc....Huge market.
They buy the purest ingredients and compound them to the form, exact dosage, % of THC, and dispense.. There is NO FDA here...no patents etc...Millions of dollars and years for studies are NOT needed like OWCP...and they might not even get FDA approval for psoriasis ...10% get approved of submissions to the fda. Also...they have a built in customer base already in NWAV clinics... .Alternative Medicine Centers of America. Robert Weber is the CEO of NWAV and RSII.
In other word...OWCP like (featuring topicals, creams, orals mainly but all forms of medicinal cannabis) but no FDA route..compounding pharmacy with labs and physicians, chemists, pharmacists....etc...Dont have to wait years for FDA approval.. .Products will be available quickly and revenues will follow fast..... THERE IS NO BETTER MODEL IN THE MEDICINAL CANNABIS INDUSTRY....SPENDING MILLIONS ON TRIALS, STUDYS, PROTOCOL REQUIREMENTS, AND THE 1-2 YR TIME FRAME FROM PHASE 1-2 STUDIES....PLUS THERE ARE NO GUARANTEES.....AND 10% OF PRODUCT SUBMISSIONS EVER GET APPROVED BY THE FDA...10% THATS IT. LIKE I SAID, FOR THE MEDICINAL CANNABIS SPACE....NOTHING BETTER THAN THE RSII MODEL.
So lets compare OWCP to RSII....
REGARDING RSII's CURRENT MARKET CAP: The market cap valuation of RSII is based on current share price...RSII is $3m at .0135...my point is RSII is EXTREMELY UNDERVALUED at these prices...hope this helps. Lets put $75M MC valuation on RSII which is imo about right in these stage and the sector. That would put the PPS of RSII approximately at about .20 cents...and that can only go up from here once they start rolling out the business and scaling it.
1- market valuation OWCFP $325M $2.19 pps vs RSII $5M .0135 pps
2- OWCP- make take years and cost millions of dollars to do studies to submit a product to the FDA for approval...and only 10% ever get approved....VS. S RSII- will have precise forms of med cannabis ingredients to be compound and dispensed in different forms as soon as they start which is very soon. No studies required...Cash requirements minimal, Revs immediate.
3- OWCP Float about 150M vs. RSII about 225M
"Our team has met with business operators that have real experience and expertise in multiple states and several business verticals within the cannabis industry," commented Management. "The business focus will center on working with physicians and pharmacists groups on the Research and Development of new, cutting edge treatments within the medical cannabis industry. Shareholders are encouraged to stay tuned to upcoming press releases and social media updates, where a detailed plan for RSII's entrance into this sector will be outlined."
Look & Listen at the video on Facebook with outside one of the labs of a compounding pharmacy: https://www.facebook.com/RisingIndiaUSA/?hc_r...mp;fref=nf
1- What is “compounding”?
In general, compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.
2-Why do some patients need compounded drugs?
Sometimes, the health needs of a patient cannot be met by an FDA-approved medication. For example: if a patient has an allergy and needs a medication to be made without a certain dye; or
if an elderly patient or a child can’t swallow a pill and needs a medicine in a liquid form that is not otherwise available.
3-Are compounded drugs approved by the FDA?
Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, or effectiveness of compounded drugs. Consumers and health professionals rely on the drug approval process to ensure that drugs are safe and effective and made in accordance with Federal quality standards. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.
Generally, state boards of pharmacy will continue to have primary responsibility for the day-to-day oversight of state-licensed pharmacies that compound drugs in accordance with the conditions of section 503A of the FDCA, although FDA retains some authority over their operations. However, outsourcing facilities that register under section 503B are regulated by FDA and must comply with CGMP requirements and will be inspected by FDA according to a risk-based schedule.
Here is an very interesting post for RSII...Seems that OWCP Company strategies and mindset of investors is changing....Our RSII MODEL is now being talked about on the OWCP board....RSII has compounding labs/pharmacies already in place and we seen one of them with a team of pharmacists, chemists, physicians, etc. that they will be branding and scaling under Rising BioSciences...The CC confirmed it...
I believe the pharmacist/chemist with 30YRS of experience in compounding and has done alot with medicinal cannabis forms said."We will revolutionize the med cannabis industry...no one else is doing what we will be doing in this space." That is pretty much word for word what he said.
GLTA
$OWCP VS. $RSII Med cannabis sector producst but different biz models>>>
Med Cannabis is very safe and not under the same regs as rec cannabis.
RSII REVIEW OF CONF. CALL on 2/24/17 & DD:
If you missed the Conf. Call yesterday ...here is a good summary and some DD:
RSII business model confirmed today on CC... There model is sort of like OWCP's but without all the FDA guidelines, indications, submission, trials, and all the COSTS that going into getting a product ready to submit to the FDA...That is very risky, costly and may never earn a dime in profit or revenue.....NOW RSII will have A team of pharmacists, chemists, physicians, etc..will be creating pharm grade medicinal cannabis product with the highest quality of ingredients and calibrated with precise accuracy. All forms of cannabis, but mainly topicals, creams, and orals. ..No one in the industry is doing this with precise accuracy...they will be the first... They come short of announcing they will supply to NWAV clinics (Alternative Medicine Centers of America) but if you read between the lines, its pretty much a done deal....Robert Weber is the CEO of both and he basicly said they had to separate the disposing/compounding side from the patient/clinic side as per their lawyers due to regulations. Medicinal Cannabis will be branded and marketed under their name Rising Biosciences. Mail order, clinics, prescribing md's, etc....Huge market.
They buy the purest ingredients and compound them to the form, exact dosage, % of THC, and dispense.. There is NO FDA here...no patents etc...Millions of dollars and years for studies are NOT needed like OWCP...and they might not even get FDA approval for psoriasis ...10% get approved of submissions to the fda. Also...they have a built in customer base already in NWAV clinics... .Alternative Medicine Centers of America. Robert Weber is the CEO of NWAV and RSII.
In other word...OWCP like (featuring topicals, creams, orals mainly but all forms of medicinal cannabis) but no FDA route..compounding pharmacy with labs and physicians, chemists, pharmacists....etc...Dont have to wait years for FDA approval.. .Products will be available quickly and revenues will follow fast..... THERE IS NO BETTER MODEL IN THE MEDICINAL CANNABIS INDUSTRY....SPENDING MILLIONS ON TRIALS, STUDYS, PROTOCOL REQUIREMENTS, AND THE 1-2 YR TIME FRAME FROM PHASE 1-2 STUDIES....PLUS THERE ARE NO GUARANTEES.....AND 10% OF PRODUCT SUBMISSIONS EVER GET APPROVED BY THE FDA...10% THATS IT. LIKE I SAID, FOR THE MEDICINAL CANNABIS SPACE....NOTHING BETTER THAN THE RSII MODEL.
So lets compare OWCP to RSII....
REGARDING RSII's CURRENT MARKET CAP: The market cap valuation of RSII is based on current share price...RSII is $3m at .0135...my point is RSII is EXTREMELY UNDERVALUED at these prices...hope this helps. Lets put $75M MC valuation on RSII which is imo about right in these stage and the sector. That would put the PPS of RSII approximately at about .20 cents...and that can only go up from here once they start rolling out the business and scaling it.
1- market valuation OWCFP $325M $2.19 pps vs RSII $5M .0135 pps
2- OWCP- make take years and cost millions of dollars to do studies to submit a product to the FDA for approval...and only 10% ever get approved....VS. S RSII- will have precise forms of med cannabis ingredients to be compound and dispensed in different forms as soon as they start which is very soon. No studies required...Cash requirements minimal, Revs immediate.
3- OWCP Float about 150M vs. RSII about 225M
"Our team has met with business operators that have real experience and expertise in multiple states and several business verticals within the cannabis industry," commented Management. "The business focus will center on working with physicians and pharmacists groups on the Research and Development of new, cutting edge treatments within the medical cannabis industry. Shareholders are encouraged to stay tuned to upcoming press releases and social media updates, where a detailed plan for RSII's entrance into this sector will be outlined."
Look & Listen at the video on Facebook with outside one of the labs of a compounding pharmacy: https://www.facebook.com/RisingIndiaUSA/?hc_r...mp;fref=nf
1- What is “compounding”?
In general, compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.
2-Why do some patients need compounded drugs?
Sometimes, the health needs of a patient cannot be met by an FDA-approved medication. For example: if a patient has an allergy and needs a medication to be made without a certain dye; or
if an elderly patient or a child can’t swallow a pill and needs a medicine in a liquid form that is not otherwise available.
3-Are compounded drugs approved by the FDA?
Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, or effectiveness of compounded drugs. Consumers and health professionals rely on the drug approval process to ensure that drugs are safe and effective and made in accordance with Federal quality standards. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.
Generally, state boards of pharmacy will continue to have primary responsibility for the day-to-day oversight of state-licensed pharmacies that compound drugs in accordance with the conditions of section 503A of the FDCA, although FDA retains some authority over their operations. However, outsourcing facilities that register under section 503B are regulated by FDA and must comply with CGMP requirements and will be inspected by FDA according to a risk-based schedule.
Here is an very interesting post for RSII...Seems that OWCP Company strategies and mindset of investors is changing....Our RSII MODEL is now being talked about on the OWCP board....RSII has compounding labs/pharmacies already in place and we seen one of them with a team of pharmacists, chemists, physicians, etc. that they will be branding and scaling under Rising BioSciences...The CC confirmed it...
I believe the pharmacist/chemist with 30YRS of experience in compounding and has done alot with medicinal cannabis forms said."We will revolutionize the med cannabis industry...no one else is doing what we will be doing in this space." That is pretty much word for word what he said.
GLTA
(2)
(0)Scroll down for more posts ▼